Physician profile
Anlin Xu
NPI 1285681007
$15,813.39
in general payments reported to CMS, 2019-2025
37 companies · $3,818 in 2025
The $3,818 reported for 2025 was more than what 84% of Allergy providers received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,085 · 2020: $1,205 · 2021: $3,487 · 2022: $2,435 · 2023: $2,339 · 2024: $1,446 · 2025: $3,818.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,568 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,568.49 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,148.52 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $3,122.50 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $2,298.27 | 2019-2025 | Xolair |
| Genzyme Corporation | $1,617.01 | 2019-2025 | |
| Csl Behring | $584.56 | 2020-2025 | Hizentra, Haegarda |
| Novartis Pharmaceuticals Corporation | $535.99 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $443.54 | 2019-2025 | Dupixent |
| Amgen INC. | $442.69 | 2022-2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $406.38 | 2025 | Neffy |
| Teva Pharmaceuticals USA, INC. | $332.27 | 2019-2020 | |
| Pfizer INC. | $300.46 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $257.27 | 2020-2025 | Takhzyro, Hyqvia, Cuvitru |
| Organon LLC | $242.11 | 2025 | Vtama, Nexplanon |
| Incyte Corporation | $231.07 | 2021-2025 | Opzelura, Opzelura |
| Galderma Laboratories, L.P. | $216.69 | 2025 | Nemluvio |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $194.64 | 2022 | |
| Alk-Abello, INC | $179.18 | 2019-2023 | Odactra, Grastek |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.57 | 2020-2022 | |
| Allergan, INC. | $125.00 | 2020 | |
| Horizon Therapeutics Plc | $117.21 | 2022 | |
| Lilly USA, LLC | $98.78 | 2025 | Ebglyss |
| Leo Pharma INC. | $79.59 | 2022-2024 | Adbry |
| Grifols Shared Services North America, INC. | $72.27 | 2019 | |
| Circassia INC. | $64.69 | 2019-2020 | |
| Octapharma USA, INC. | $64.48 | 2023 | Cutaquig |
| Kowa Pharmaceuticals America, INC. | $63.31 | 2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $61.70 | 2021 | |
| Optinose US, INC. | $56.36 | 2019-2025 | |
| Kaleo, INC. | $51.35 | 2019-2024 | Auvi-Q |
| Grifols USA, LLC | $50.45 | 2024 | Xembify |
| Abbvie INC. | $40.87 | 2022-2023 | Rinvoq |
| Ionis Pharmaceuticals, INC. | $39.60 | 2025 | Dawnzera |
| Hospira, INC. | $25.51 | 2025 | |
| Genentech, INC. | $23.17 | 2021 | |
| Mylan Specialty L.P. | $22.58 | 2020 | |
| Covis Pharma Gmbh | $21.53 | 2019 | |
| Uswm, LLC | $17.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anlin Xu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.